Elacestrant

Edit links
From Wikipedia, the free encyclopedia

This is an old revision of this page, as edited by Citation bot (talk | contribs) at 11:09, 8 December 2019 (Removed URL that duplicated unique identifier. | You can use this bot yourself. Report bugs here.| Activated by User:Nemo bis | via #UCB_webform). The present address (URL) is a permanent link to this revision, which may differ significantly from the current revision.

Elacestrant
Clinical data
Other namesRAD-1901, ER-306323
Routes of
administration		Oral
Identifiers
  • (6R)-6-{2-[Ethyl({4-[2-(ethylamino)ethyl]phenyl}methyl)amino]-4-methoxyphenyl}-5,6,7,8-tetrahydronaphthalen-2-ol
CAS Number
PubChem CID
ChemSpider
UNII
KEGG
ECHA InfoCard100.312.890 Edit this at Wikidata
Chemical and physical data
FormulaC30H38N2O2
Molar mass458.63492 g/mol g·mol−1
3D model (JSmol)
  • CCNCCC1=CC=C(C=C1)CN(CC)C2=C(C=CC(=C2)OC)C3CCC4=C(C3)C=CC(=C4)O
  • InChI=1S/C30H38N2O2/c1-4-31-17-16-22-6-8-23(9-7-22)21-32(5-2)30-20-28(34-3)14-15-29(30)26-11-10-25-19-27(33)13-12-24(25)18-26/h6-9,12-15,19-20,26,31,33H,4-5,10-11,16-18,21H2,1-3H3/t26-/m1/s1
  • Key:SIFNOOUKXBRGGB-AREMUKBSSA-N

Elacestrant (INN) (developmental code names RAD-1901, ER-306323) is a nonsteroidal combined selective estrogen receptor modulator (SERM) and selective estrogen receptor degrader (SERD) (described as a "SERM/SERD hybrid (SSH)") that was discovered by Eisai and is under development by Radius Health and Takeda for the treatment of menopausal vasomotor symptoms (hot flashes) and estrogen receptor (ER)-positive advanced breast cancer, as well as endometrial cancer and kidney cancer.[1][2][3][4][5] As of September 2016, it is in phase II clinical trials for vasomotor symptoms and breast cancer.[2][5] Elacestrant has dose-dependent, tissue-selective estrogenic and antiestrogenic activities, with biphasic weak partial agonist activity at the ER at low doses and antagonist activity at higher doses.[3] It shows agonistic activity on bone and antagonistic activity on breast and uterine tissues.[4] Unlike the SERD fulvestrant, elacestrant is able to readily cross the blood-brain-barrier into the central nervous system, where it can target breast cancer metastases in the brain,[3][4] and is orally bioavailable and does not require intramuscular injection.[3][4]

See also

References

  1. ^ http://www.who.int/medicines/publications/druginformation/LP_115.pdf
  2. ^ a b http://adisinsight.springer.com/drugs/800027755
  3. ^ a b c d Wardell, Suzanne E.; Nelson, Erik R.; Chao, Christina A.; Alley, Holly M.; McDonnell, Donald P. (1 October 2015). "Evaluation of the pharmacological activities of RAD1901, a selective estrogen receptor degrader". Endocrine-Related Cancer. 22 (5): 713–724. doi:10.1530/ERC-15-0287. ISSN 1479-6821. PMC 4545300. PMID 26162914.
  4. ^ a b c d Garner, Fiona; Shomali, Maysoun; Paquin, Dotty; Lyttle, C. Richard; Hattersley, Gary (October 2015). "RAD1901: a novel, orally bioavailable selective estrogen receptor degrader that demonstrates antitumor activity in breast cancer xenograft models". Anti-Cancer Drugs. 26 (9): 948–956. doi:10.1097/CAD.0000000000000271. ISSN 0959-4973. PMC 4560273. PMID 26164151.
  5. ^ a b Hattersley, Gary; Harris, Alan G.; Simon, James A.; Constantine, Ginger D. (2016). "Clinical investigation of RAD1901, a novel estrogen receptor ligand, for the treatment of postmenopausal vasomotor symptoms: a phase 2 randomized, placebo-controlled, double-blind, dose-ranging, proof-of-concept trial". Menopause. 24 (1): 92–99. doi:10.1097/gme.0000000000000726. ISSN 1072-3714. PMID 27575546.

External links


Stub icon

This antineoplastic or immunomodulatory drug article is a stub. You can help Wikipedia by expanding it.

Stub icon

This drug article relating to the genito-urinary system is a stub. You can help Wikipedia by expanding it.

Retrieved from "https://en.wikipedia.org/w/index.php?title=Elacestrant&oldid=929811441"